CD274 and cancer: However, in GC, from the perspective of immune modulation, ATRA was shown to reduce the capacity of T cells to kill cancer cells by upregulating the expression of PD-L1, reducing the anticancer effects of PD-L1 antibodies, and reducing T cells activation in vivo (57), which is different from the effects of ATRA reported in other types of cancer (58).